Analysts have been eager to weigh in on the Healthcare sector with new ratings on Gilead Sciences (GILD – Research Report), Bausch + Lomb Corporation (BLCO – Research Report) and Humana (HUM – Research Report).
Gilead Sciences (GILD)
In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences, with a price target of $90.00. The company’s shares closed last Monday at $79.07.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $92.39, a 16.0% upside from current levels. In a report issued on January 22, Leerink Partners also maintained a Hold rating on the stock with a $123.00 price target.
See the top stocks recommended by analysts >>
Bausch + Lomb Corporation (BLCO)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Bausch + Lomb Corporation, with a price target of $21.00. The company’s shares closed last Monday at $14.54, close to its 52-week low of $14.10.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch + Lomb Corporation with a $18.20 average price target.
Humana (HUM)
Wells Fargo analyst Steve Baxter maintained a Buy rating on Humana yesterday and set a price target of $413.00. The company’s shares closed last Monday at $365.94, close to its 52-week low of $342.69.
According to TipRanks.com, Baxter is a 2-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Humana with a $441.88 average price target, representing a 21.7% upside. In a report issued on January 17, Oppenheimer also maintained a Buy rating on the stock with a $630.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
- Gilead’s $320M Investment Sends Arcus Biosciences (NYSE: RCUS) Stock Soaring
- Guggenheim ups CymaBay price target to $28, sees M&A potential
- Gilead call volume above normal and directionally bullish
- AstraZeneca helped in competitive debate by Gilead’s EVOKE-01 miss, says BofA
- FDA instructs drugmakers to add T cell malignancy risk info to CAR-T labels
